P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.

• C. Li,
• H. Geng,
• X. Zong,
• J. Zhou,
• Y. Zhang,
• J. Li,
• S. Jia,
• D. Wu

Affiliations

C. Li

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

H. Geng

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

X. Zong

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

J. Zhou

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

Y. Zhang

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

J. Li

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

S. Jia

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University

D. Wu

1 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affliated Hospital of Soochow University